Pharma and telehealth firms battle to own GLP-1 patient journey
Industry analysis examines how manufacturers, pharmacies and digital platforms compete for direct relationships with obesity drug patients.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 17 11:52 ETSource: Pharmaceutical Executive
The wire
- 01Pharmaceutical Executive examines competition to control the GLP-1 patient journey.
- 02Direct-to-patient channels are reshaping how obesity drugs are marketed and dispensed.
- 03Which model wins on retention and outcomes is unresolved.
From the source
Read at news.google.comThe Battle to Own the GLP-1 Patient Journey